Change in multiple sclerosis prevalence over time in Australia 2010–2017 utilising disease-modifying therapy prescription data

Abstract

Objective:

Determine the prevalence of multiple sclerosis (MS) in Australia in 2017 using MS-specific disease-modifying therapy (DMT) prescription data and estimate the change in prevalence from 2010.

Methods:

DMT prescriptions were extracted from Australia’s Pharmaceutical Benefits Scheme (PBS) data for January–December 2017. Percentages of people with MS using DMTs (DMT penetrance) were calculated using data from the Australian MS Longitudinal Study. Prevalence was estimated by dividing the total number of monthly prescriptions by 12 (except alemtuzumab), adjusted for DMT penetrance and Australian population estimates. Prevalences in Australian states/territories were age-standardised to the Australian population. Comparisons with 2010 prevalence data were performed using Poisson regression.

Results:

Overall DMT penetrance was 64%, and the number of people with MS in Australia in 2017 was 25,607 (95% confidence interval (CI): 24,874–26,478), a significant increase of 4324 people since 2010 (p < 0.001). The prevalence increased significantly from 95.6/100,000 (2010) to 103.7/100,000 (2017), with estimates highest in Tasmania in 2017 (138.7/100,000; 95% CI: 137.2–140.1) and lowest in Queensland (74.6/100,000; 95% CI: 73.5–75.6). From 2010 to 2017 using the median latitudes for each state/territory, the overall latitudinal variation in MS prevalence was an increase of 3.0% per degree-latitude.

Conclusion:

Consistent with global trends, Australia’s MS prevalence has increased; this probably reflecting decreased mortality, increased longevity and increased incidence.

Keywords

Australian Multiple Sclerosis Longitudinal Study Australian Pharmaceutical Benefits Scheme immunomodulating agent health economics

Get full access to this article

View all access options for this article.

References

Simpson

Jr Taylor

van der Mei

The role of epidemiology in MS research: Past successes, current challenges and future potential. Mult Scler 2015; 21(8): 969–977.

Browne

Chandraratna

Angood

, et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology 2014; 83(11): 1022–1024.

Feigin

Abajobir

Abate

, et al. Global, regional, and national burden of neurological disorders during 1990–2015: A systematic analysis for the global burden of disease study 2015. Lancet Neurol 2017; 16: 877–897.

Ribbons

Lea

Tiedeman

, et al. Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study. Mult Scler 2017; 23(8): 1063–1071.

Palmer

Hitchens

Simpson

Jr , et al. A novel method for calculating prevalence of multiple sclerosis in Australia. Mult Scler 2013; 19(13): 1704–1711.

Palmer

Colman

O’Leary

, et al. The economic impact of multiple sclerosis in Australia in 2010. Mult Scler 2013; 19(12): 1640–1646.

Broadley

Barnett

Boggild

, et al. A new era in the treatment of multiple sclerosis. Med J Aust 2015; 203: 139–141.

Coles

Compston

Selmaj

, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359(17): 1786–1801.

Australian Government Department of Health. The pharmaceutical benefits scheme (PBS), https://www.pbs.gov.au/browse/rpbs

10.

Willis

Reynolds

Keleher

Understanding the Australian health care system. Chatswood, NSW, Australia: Elsevier Health Sciences, 2016.

11.

Australian Government Department of Human Services. Pharmaceutical benefits scheme (PBS), https://www.humanservices.gov.au/individuals/services/medicare/pharmaceutical-benefits-scheme

12.

Australian Government Department of Human Services. Pharmaceutical benefits schedule item reports, http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp

13.

Chen

Taylor

Palmer

, et al. Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis. Mult Scler 2019; 25: 994–1004.

14.

Taylor

Palmer

Simpson

Jr , et al. Assessing possible selection bias in a national voluntary MS longitudinal study in Australia. Mult Scler 2013; 19(12): 1627–1631.

15.

Ahmad

Campbell

van der Mei

, et al. The health economics of multiple scelrosis in Australia in 2017. Multiple Sclerosis Research Australia, 2018, https://msra.org.au/news/ms-economic-impact-report-launch/

16.

Australian Bureau of Statistics (ABS). 3101.0 – Australian demographic statistics, Sep 2017, http://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/819D0CD114A1BACFCA2582B20017D835?opendocument

17.

Australian Bureau of Statistics (ABS). The Australian statistical geography standard, http://www.abs.gov.au/websitedbs/D3310114.nsf/home/remoteness+structure

18.

Breslow

Day

Statistical methods in cancer research. Oxford: Oxford University Press, 1991.

19.

Polman

Reingold

Banwell

, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292–302.

20.

Thompson

Banwell

Barkhof

, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162–173.

21.

Tao

Simpson

Jr van der Mei

, et al. Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87(12): 1343–1349.

22.

Simpson

Jr Blizzard

Otahal

, et al. Latitude is significantly associated with the prevalence of multiple sclerosis: A meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82(10): 1132–1141.

23.

McCall

Brereton

Dawson

, et al. Frequency of multiple sclerosis in three Australian cities – Perth, Newcastle, and Hobart. J Neurol Neurosurg Psychiatry 1968; 31(1): 1–9.

24.

Hammond

McLeod

Millingen

, et al. The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain 1988; 111(Pt. 1): 1–25.

25.

Wallin

Culpepper

Campbell

, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology 2019; 92(10): e1029–e1040.

26.

Chen

Taylor

Blizzard

, et al. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. J Neurol Neurosurg Psychiatry 2018; 89(11): 1200–1207.

27.

Bargagli

Colais

Agabiti

, et al. Prevalence of multiple sclerosis in the Lazio region, Italy: Use of an algorithm based on health information systems. J Neurol 2016; 263(4): 751–759.

28.

Salhofer-Polanyi

Cetin

Leutmezer

, et al. Epidemiology of multiple sclerosis in Austria. Neuroepidemiology 2017; 49(1–2): 40–44.

29.

Jokubaitis

Spelman

Lechner-Scott

, et al. The Australian multiple sclerosis (MS) immunotherapy study: A prospective, multicentre study of drug utilisation using the MSBase platform. PLoS ONE 2013; 8(3): e59694.

30.

Australian Bureau of Statistics. 3412.0 – Migration, Australia, 2017–18, http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/3412.0Explanatory+Notes12017–18

31.

Taylor

Palmer

Simpson

Jr , et al. Assessing possible selection bias in a national voluntary MS longitudinal study in Australia. Mult Scler 2013; 19(12): 1627–1631.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.20 MB